Menu Back toS12-What-is-Expected-to-MA-MSL

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S12] What is Expected to MA/MSL?

Session Chair(s)

Yasuyuki  Katayama, MD, PhD

Yasuyuki Katayama, MD, PhD

  • Corporate Officer, Country Medical Director and Head of Medical Japan
  • Pfizer Japan Inc., Japan
Many pharmaceutical companies are reinforcing function of Medical affairs in recent years. In particular, MA/MSL are the core function within medical activity and they have various responsibilities or skills. Also, some groups of pharmaceutical industry made a statement about role or responsibility of MA/MSL. In this session, speakers from academia, pharmaceutical companies and regulatory authority will share their perspective on expectation to MA/MSL. The workshop is designed to discuss what is expected to MA/MSL with participants. D ring this workshop, we will be able to identify common sense or gaps about role of MA/MSL among pharmaceutical industry groups and to clarify position or responsibility of MA/MSL in Japan.


Toshiya  Nishibe, MD, PhD

What is Medical Affairs or Medical Science Liaison? -Questions from Medical Doctor-

Toshiya Nishibe, MD, PhD

  • Professor, Department of Cardiovascular Surgery
  • Tokyo Medical University, Japan
Takamasa  Horio, JD

How MA/MSL Should Be?

Takamasa Horio, JD

  • Legal Advisor, Compliance and Narcotics Division
  • Ministry of Health, Labour and Welfare (MHLW), Japan
Takeshi  Nishimura, PhD

Consensus Statement on MA / MSL activities

Takeshi Nishimura, PhD

  • Senior Director, Medical Affairs Regional Function Head
  • Sumitomo Dainippon Pharma Co., Ltd., Japan
Takeshi  Imaoka, MD, PhD

How MA/MSL Good Look Like? – PhRMA Perspective-

Takeshi Imaoka, MD, PhD

  • Senior Director, Database Research Medicine Development Unit
  • Eli Lilly Japan K.K., Japan